A systematic review of the effectiveness of adalimumab

TABLE 12 Description of included RCTs and baseline patient characteristics: infliximab (cont’d)
Study and description Interventions No. of Mean Mean No. of On On Mean
patients age disease previous steroids NSAIDs baseline
(years) duration DMARDs (%) (%) HAQ
(years) score
Quinn et al., 2005141 (Median)
UK, single centre, double-blind Placebo + MTX (starting 7.5, increasing to 10 53 0.5 0 0 NR 1.3
Infliximab treatment: repeated infusion 15–25 mg per week according to clinical response)
at 0, 2 and 6 weeks then every 8 weeks Infliximab 3 mg kg –1 i.v. every 8 weeks + MTX 10 51 0.6 0 0 1.3
until week 46 (as above) (Not (Not
Duration of follow-up: 54 weeks e
permitted) permitted)
a
Extension study with continuous treatment and follow-up to 102 weeks not included in the current review; see text for details (p. 53).
b
Excluding MTX.
c –1 Open label, non-comparative extension with three additional infusions of infliximab 10 mg kg at weeks 12, 20 and 28 and follow-up to week 40 not included in the current review.
d –1 Patients in placebo arm switched to infliximab 3 mg kg at week 22 and all group continued treatments for 46 weeks. Results beyond 22 weeks are not included in the current
review.
e
Open-label extension and follow-up to 104 weeks not included in the current review as other DMARDs could be introduced during the extension.
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 42
57